The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man

References

• Åsberg M., Cronholm B., Sjöqvist F., Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br. Med. J. 1971; 3: 31–34
   PubMedGoogle Scholar
• Alexanderson B., Borgå O. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur. J. Clin. Pharmacol. 1973; 5: 174–180, [CROSSREF]
   Web of Science ®Google Scholar
• Alexanderson B., Price Evans D. A., Sjöqvist F. Steady‐state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br. Med. J. 1969; 4: 764–768, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Baier‐Weber B., Prox A., Wachsmuth H., Breyer‐Pfaff U. Glucuronides of hydroxylated metabolites of amitriptyline and nortriptyline isolated from rat bile. Drug Metab. Dispos. 1988; 16(3)490–496
   PubMed Web of Science ®Google Scholar
• Balant‐Gorgia A. E., Schulz P., Dayer P., Balant L., Kubli A., Gertsch C., Garrone G. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch. Psychiatr. Nervenkr. 1982; 232: 215–222
   PubMedGoogle Scholar
• Baumann P. Pharmacokinetic‐pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 1996; 31(6)444–469, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Baumann P., Jonzier‐Perey M., Koeb L., Küpfer A., Tinguely D., Schöpf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int. Clin. Psychopharmacol. 1986; 1: 102–112, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Baumann P., Meyer J. W., Amey M., Baettig D., Bryois C., Jonzier‐Perey M., Koeb L., Monney C., Woggon B. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit. 1992; 14: 1–8, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Becher B., Fischer W., Taneri Z., Scholz E., Müller W. E., Breyer‐Pfaff U. Urinary metabolites of amitriptylinoxide and amitriptyline in single‐dose experiments and during continuous therapy. Psychopharmacology 1992; 106: 303–310, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Al‐Sarraj S. Metabolism of amitriptyline, nortriptyline, imipramine and desipramine to yield hydroxylamines. J. Pharm. Pharmacol. 1973; 25(4)335–336, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Hutt A. J. In vitro metabolism in the rabbit of desipramine and nortriptyline to yield carboxylic acids. J. Pharm. Pharmacol. 1982; 34(9)614, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady‐state plasma level. Eur. J. Clin. Pharmacol. 1972; 4: 201–205, [CROSSREF]
   Web of Science ®Google Scholar
• Bertilsson L., Mellström B., Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10‐hydroxy‐metabolites of nortriptyline. Life Sci. 1979; 25: 1285–1292, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Eichelbaum M., Mellström B., Säwe J., Schulz H. U., Sjöqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci. 1980; 27: 1673–1677, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Nordin C., Otani K., Resul B., Scheinin M., Siwers B., Sjöqvist F. Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clin. Pharmacol. Ther. 1986; 40(3)261–267, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Dahl M. L., Dalén P., Al‐Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002; 53: 111–122, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bhagwat S. V., Bhamre S., Boyd M. R., Ravindranath V. Cerebral metabolism of imipramine and a purified flavin‐containing monooxygenase from human brain. Neuropsychopharmacology 1996; 15(2)133–142, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bickel M. H. Liver metabolic reactions: tertiary amine N‐dealkylation, tertiary amine N‐oxidation, N‐oxide reduction, and N‐oxide N‐dealkylation. Arch. Biochem. Biophys. 1971; 148: 54–62, [CROSSREF]
   Web of Science ®Google Scholar
• Bickel M. H. Metabolism of antidepressants. Psychotropic Agents, Part I, F. Hoffmeister, G. Stille. Handbook of Experimental Pharmacology, Springer, Berlin Heidelberg New York 1980; Vol. 55: 551–572
   Google Scholar
• Bock J. L., Giller E., Gray S., Jatlow P. Steady‐state plasma concentrations of cis‐ and trans‐10‐OH amitriptyline metabolites. Clin. Pharmacol. Ther. 1982; 31(5)609–616, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Nill K. Stereoselective reversible ketone formation from 10‐hydroxylated nortriptyline metabolites in human liver. Xenobiotica 1995; 25(12)1311–1325
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Nill K. High‐affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo‐keto reductases from human liver. Biochem. Pharmacol. 2000; 59: 249–260, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Ewert M., Wiatr R. Comparative single‐dose kinetics of amitriptyline and its N‐oxide in a volunteer. Arzneim.‐Forsch. 1978; 28(10b)1916–1920
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Prox A., Wachsmuth H., Yao P. Phenolic metabolites of amitriptyline and nortriptyline in rat bile. Drug Metab. Dispos. 1987; 15(6)882–889
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Becher B., Nusser E., Nill K., Baier‐Weber B., Zaunbrecher D., Wachsmuth H., Prox A. Quaternary N‐glucuronides of 10‐hydroxylated amitriptyline metabolites in human urine. Xenobiotica 1990; 20(7)727–738
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Pfandl B., Nill K., Nusser E., Monney C., Jonzier‐Perey M., Baettig D., Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther. 1992; 52(4)350–358
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Fischer D., Winne D. Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Drug Metab. Dispos. 1997; 25(3)340–345
   PubMed Web of Science ®Google Scholar
• Breyer‐Pfaff U., Mey U., Green M. D., Tephly T. R. Comparative N‐glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP‐glucuronosyltransferases and liver microsomes. Drug Metab. Dispos. 2000; 28(8)869–872
   PubMed Web of Science ®Google Scholar
• Burch J. E. The demethylation of amitriptyline: a cross‐over study of steady‐state plasma levels of amitriptyline and nortriptyline in depressed patients. Psychopharmacology 1983; 80: 254–258, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burch J. E., Hullin R. P. Amitriptyline pharmacokinetics. A crossover study with single doses of amitriptyline and nortriptyline. Psychopharmacology 1981; 74: 35–42, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burch J. E., Herries D. G. The demethylation of amitriptyline administered by oral and intramuscular routes. Psychopharmacology 1983; 80: 249–253, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burch J. E., Roberts S. G., Raddats M. A. Amitriptyline and its basic metabolites determined in plasma by gas chromatography. J. Chromatogr. 1984; 308: 165–179, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cashman J. R., Park S. B., Berkman C. E., Cashman L. E. Role of hepatic flavin‐containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem.‐Biol. Interact. 1995; 96: 33–46, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Corona G. L., Maffei Facino R. Identification and evaluation of amitryptiline and its basic metabolites in rabbit urine. Biochem. Pharmacol. 1968; 17: 2045–2050, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dahl M. L., Nordin C., Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther. Drug Monit. 1991; 13(3)189–194, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dahl M. L., Bertilsson L., Nordin C. Steady‐state plasma levels of nortriptyline and its 10‐hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 1996; 123: 315–319, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dahl‐Puustinen M. L., Åberg‐Wistedt A., Bertilsson L. Glucuronidation of amitriptyline in man in vivo. Pharmacol. Toxicol. 1989a; 65(1)37–39
   PubMedGoogle Scholar
• Dahl‐Puustinen M. L., Perry T. L., Jr., Dumont E., von Bahr C., Nordin C., Bertilsson L. Stereoselective disposition of racemic E‐10‐hydroxynortriptyline in human beings. Clin. Pharmacol. Ther. 1989b; 45(6)650–656
   PubMed Web of Science ®Google Scholar
• Dahl‐Puustinen M. L., Dumont E., Bertilsson L. Glucuronidation of E‐10‐hydroxynortriptyline in human liver, kidney, and intestine. Organ‐specific differences in enantioselectivity. Drug Metab. Dispos. 1989c; 17(4)433–436
   PubMed Web of Science ®Google Scholar
• Dalén P., Dahl M. L., Bernal Ruiz M. L., Nordin J., Bertilsson L. 10‐Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 1998; 63(4)444–452
   PubMed Web of Science ®Google Scholar
• Desta Z., Zhao X., Shin J. G., Flockhart D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41(12)913–958, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dumont E., von Bahr C., Perry T. L., Jr., Bertilsson L. Glucuronidation of the enantiomers of E‐10‐hydroxynortriptyline in human and rat liver microsomes. Pharmacol. Toxicol. 1987; 61: 335–341, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Eschenhof E., Rieder J. Untersuchungen über das Schicksal des Antidepressivums Amitriptylin im Organismus der Ratte und des Menschen. Arzneim.‐Forsch. 1969; 19(6)957–960
   PubMedGoogle Scholar
• Garland W. A., Muccino R. R., Min B. H., Cupano J., Fann W. E. A method for the determination of amitriptyline and its metabolites nortriptyline, 10‐hydroxyamitriptyline, and 10‐hydroxynortriptyline in human plasma using stable isotope dilution and gas chromatography‐chemical ionization mass spectrometry (GC‐CIMS). Clin. Pharmacol. Ther. 1979; 25(6)844–856, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Green M. D., Tephly T. R. Glucuronidation of amine substrates by purified and expressed UDP‐glucuronosyltransferase proteins. Drug Metab. Dispos. 1998; 26(9)860–867, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Green M. D., King C. D., Mojarrabi B., Mackenzie P. I., Tephly T. R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP‐glucuronosyltransferase 1A3. Drug Metab. Dispos. 1998; 26(6)507–512, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hiemke C., Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 2000; 85: 11–28, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hucker H. B. Metabolism of amitriptyline. Pharmacologist 1962; 4: 171
   Google Scholar
• Hucker H. B., Balletto A. J., Demetriades J., Arison B. H., Zacchei A. G. Urinary metabolites of amitriptyline in the dog. Drug Metab. Dispos. 1977; 5(2)132–142, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hutt V., Theodor R., Pabst G., Dilger C., Mosberg H., Fischer W., Jaeger H. Plasma‐ und Urinkinetik von Amitriptylinoxid und seiner Metaboliten. Vergleich einer intravenösen Infusion mit einer oralen Einmalgabe bei Probanden. Arzneim.‐Forsch. 1991; 41(4)367–372
   PubMedGoogle Scholar
• Hyttel J., Christensen A. V., Fjalland B. Neuropharmacological properties of amitriptyline, nortriptyline and their metabolites. Acta Pharmacol. Toxicol. 1980; 47: 53–57
   PubMedGoogle Scholar
• Jerling M., Alván G. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring. Eur. J. Clin. Pharmacol. 1994; 46: 67–70, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jerling M., Bertilsson L., Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther. Drug Monit. 1994; 16: 1–12, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jiang Z. P., Shu Y., Chen X. P., Huang S. L., Zhu R. H., Wang W., He N., Zhou H. H. The role of CYP2C19 in amitriptyline N‐demethylation in Chinese subjects. Eur. J. Clin. Pharmacol. 2002; 58(2)109–113, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Johne A., Schmider J., Brockmöller J., Stadelmann A. M., Störmer E., Bauer S., Scholler G., Langheinrich M., Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's Wort (hypericum perforatum). J. Clin. Psychopharmacol. 2002; 22(1)46–54, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kirchheiner J., Brøsen K., Dahl M. L., Gram L. F., Kasper S., Roots I., Sjöqvist F., Spina E., Brockmöller J. CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages. Acta Psychiatr. Scand. 2001; 104: 173–192, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kitamura S., Sugihara K., Tatsumi K. A unique tertiary amine N‐oxide reduction system composed of quinone reductase and heme in rat liver. Drug Metab. Dispos. 1999; 27(1)92–97, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kitamura S., Ohashi K. N. K., Sugihara K., Ohta S. Extremely high drug‐reductase activity based on aldehyde oxidase in monkey liver. Biol. Pharm. Bull. 2001; 24(7)856–859, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kuhn R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G22355). Schweiz. Med. Wochenschr. 1957; 87: 1135–1140, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lehman J. P., Fenselau C., DePaulo J. R. Quaternary ammonium‐linked glucuronides of amitriptyline, imipramine, and chlorpromazine. Drug Metab. Dispos. 1983; 11: 221–225, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Leucht S., Hackl H. J., Steimer W., Angersbach D., Zimmer R. Effect of adjunctive paroxetine on serum levels and side‐effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology 2000; 147: 378–383, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Leuschner F., Neumann W., Doppelfeld I. S., Erdös A., Fontaine R., Gabbar H. A., Graf E. General pharmacology of amitriptylinoxide. Arzneim.‐Forsch. 1978; 28(10b)1883–1893
   PubMed Web of Science ®Google Scholar
• Madsen H., Kramer Nielsen K., Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms—a population study. Br. J. Clin. Pharmacol. 1995; 39: 433–439, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Maffei Facino R., Santagostino G., Corona G. L. Presence of an acid metabolite of amitryptiline in rabbit urine. Biochem. Pharmacol. 1970; 19: 1503–1505, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McMahon R. E., Marshall F. J., Culp H. W., Miller W. M. The metabolism of nortriptyline‐N‐methyl‐14C in rats. Biochem. Pharmacol. 1963; 12(10)1207–1217, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mellström B., von Bahr C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10‐hydroxyamitriptyline in human liver microsomes. Drug Metab. Dispos. 1981; 9(6)565–568
   PubMed Web of Science ®Google Scholar
• Mellström B., Bertilsson L., Säwe J., Schulz H. U., Sjöqvist F. E‐ and Z‐10‐hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther. 1981; 30: 189–193
   PubMed Web of Science ®Google Scholar
• Mellström B., Alván G., Bertilsson L., Potter W. Z., Säwe J., Sjöqvist F. Nortriptyline formation after single oral and intramuscular doses of amitriptyline. Clin. Pharmacol. Ther. 1982; 32: 664–667
   PubMed Web of Science ®Google Scholar
• Mellström B., Bertilsson L., Birgersson C., Göransson M., von Bahr C. E‐ and Z‐10‐hydroxylation of nortriptyline by human liver microsomes—methods and characterization. Drug Metab. Dispos. 1983; 11(2)115–119
   PubMed Web of Science ®Google Scholar
• Mellström B., Säwe J., Bertilsson L., Sjöqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin. Pharmacol. Ther. 1986; 39: 369–371
   PubMed Web of Science ®Google Scholar
• Mey U., Wachsmuth H., Breyer‐Pfaff U. Conjugation of the enantiomers of ketotifen to four isomeric quaternary ammonium glucuronides in humans in vivo and in liver microsomes. Drug Metab. Dispos. 1999; 27(11)1281–1292, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Midgley I., Hawkins D. R., Chasseaud L. F. The metabolic fate of the antidepressive agent amitriptylinoxide in man. Arzneim.‐Forsch. 1978; 28(10b)1911–1916
   PubMed Web of Science ®Google Scholar
• Nakajima M., Tanaka E., Kobayashi T., Ohashi N., Kume T., Yokoi T. Imipramine N‐glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP‐glucuronosyltransferase isoforms. Drug Metab. Dispos. 2002; 30(6)636–642, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nordin C., Bertilsson L. Active hydroxymetabolites of antidepressants. Emphasis on E‐10‐hydroxy‐nortriptyline. Clin. Pharmacokinet. 1995; 28(1)26–40, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nordin C., Bertilsson L., Otani K., Widmark A. Little anticholinergic effect of E‐10‐hydroxynortriptyline compared with nortriptyline in healthy subjects. Clin. Pharmacol. Ther. 1987; 41: 97–102, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nusser E., Nill K., Breyer‐Pfaff U. Enantioselective formation and disposition of (E)‐ and (Z)‐10‐hydroxynortriptyline. Drug Metab. Dispos. 1988; 16(3)509–511, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nusser E., Nill K., Breyer‐Pfaff U. Enantiomer analysis of E‐ and Z‐10‐hydroxyamitriptyline in human urine. J. Chromatogr. 1990; 528: 163–171, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ohara H., Miyabe Y., Deyashiki Y., Matsuura K., Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase, and aldehyde reductase of human liver. Biochem. Pharmacol. 1995; 50: 221–227, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Olesen O. V., Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA‐expressed human cytochrome P‐450 isozymes. Drug Metab. Dispos. 1997; 25(6)740–744, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Perry P. J., Zeilmann C., Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J. Clin. Psychopharmacol. 1994; 14: 230–240, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pfandl B., Mörike K., Winne D., Schareck W., Breyer‐Pfaff U. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 1992; 22(6)721–730, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pollock B. G., Everett G., Perel J. M. Comparative cardiotoxicity of nortriptyline and its isomeric 10‐hydroxymetabolites. Neuropsychopharmacology 1992; 6(1)1–10, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Calil H. M., Manian A. A., Zavadil A. P., Goodwin F. K. Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol. Psychiatry 1979; 14(4)601–613, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Powis G., DeGraw C. L. N‐oxide reduction by hemoglobin, cytochrome C and ferrous ions. Res. Commun. Chem. Pathol. Pharmacol. 1980; 30(1)143–150, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Preskorn S. H., Jerkovich G. S. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J. Clin. Psychopharmacol. 1990; 10(2)88–95, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Prox A., Breyer‐Pfaff U. Amitriptyline metabolites in human urine. Identification of phenols, dihydrodiols, glycols, and ketones. Drug Metab. Dispos. 1987; 15(6)890–896, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rollins D. E., Alván G., Bertilsson L., Gillette J. R., Mellström B., Sjöqvist F., Träskman L. Interindividual differences in amitriptyline demethylation. Clin. Pharmacol. Ther. 1980; 28(1)121–129, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Santagostino G., Maffei Facino R., Pirillo D. Urinary excretion of amitriptyline N‐oxide in humans. J. Pharm. Sci. 1973; 63(11)1690–1692
   Web of Science ®Google Scholar
• Shimoda K., Someya T., Yokono A., Morita S., Hirokane G., Takahashi S., Okawa M. Impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J. Clin. Psychopharmacol. 2002; 22(4)371–378, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Takekawa K., Kitamura S., Sugihara K., Ohta S. Non‐enzymatic reduction of aliphatic tertiary amine N‐oxides mediated by the haem moiety of cytochrome P450. Xenobiotica 2001; 31(1)11–23, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ulrich S., Läuter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin. Pharmacokinet. 2002; 41(11)853–876, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vandel B., Vandel S., Allers G., Bechtel P., Volmat R. Interaction between amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology 1979; 65: 187–190, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vandel B., Sandoz M., Vandel S., Allers G., Volmat R. Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites. Eur. J. Clin. Pharmacol. 1982; 22: 239–245, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vandel S., Bertschy G., Vandel B., Allers G., Volmat R. Amitriptyline: linear or nonlinear kinetics in every day practice?. Eur. J. Clin. Pharmacol. 1989; 37: 595–598, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vandel S., Bertschy G., Baumann P., Bouquet S., Bonin B., Francois T., Sechter D., Bizouard T. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol. Res. 1995; 31: 347–353, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K., von Moltke L. L., Greenblatt D. J. Nortriptyline E‐10‐hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme‐inducing drugs. J. Clin. Pharmacol. 1999; 39: 567–577, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K., von Moltke L. L., Greenblatt D. J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 2001; 297(1)326–337, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• von Bahr C., Steiner E., Koike Y., Gabrielsson J. Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin. Pharmacol. Ther. 1998; 64(1)18–26, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yamada H., Shimizudani T., Hatsumura M., Oguri K., Yoshimura H. Metabolic formation of dimethylamine and methylamine from basic drugs containing N‐methyl group: a newly established chromatographic assay and its application to the determination of deaminase activity. Biol. Pharm. Bull. 1993; 16(9)847–851, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ziegler D. M. Microsomal flavin‐containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds. Enzymatic Basis of Detoxication, W. B. Jakoby. Biochemical Pharmacology and Toxicology, Academic Press, New York 1980; Vol. I: 201–227
   Google Scholar
• Ziegler D. M. Molecular basis for N‐oxygenation of sec‐ and tert‐amines. Biological Oxidation of Nitrogen in Organic Molecules. Chemistry, Toxicology and Pharmacology, J. W. Gorrod, L. A. Damani. Ellis Horwood Health Science Series, Horwood, Chichester 1985; 43–52
   Google Scholar